Close

Ranbaxy Honored With Nabia Award For Excellence in New Jersey Business Expansion

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Roche Looks to Expand its Drug Production in the US

Roche is planning to expand its drug production in...

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Ranbaxy Inc., a research-based pharmaceutical company that manufactures generic product formulations, OTC and branded drug products, has been honored with the New Jersey Business Industry Association’s (NJBIA) Award for Excellence in Business Expansion and Economic Contribution to the State. 

The NJBIA award acknowledges Ranbaxy’s commitment and contribution to the State,  providing jobs for more than 700 New Jerseyans and with recent investments in its state-of-the-art manufacturing facilities in New Brunswick. NJBIA President Philip Kirschnerwill honor Ranbaxy and other recipients at an awards dinner on October 18, 2011 in Edison, NJ.

Ranbaxy entered the U.S. market in 1994 with a sales office in Raleigh, North Carolina.  It acquired Ohm Laboratories of North Brunswick, NJ, its first U.S. manufacturing facility in 1995 and subsequently relocated its North American headquarters to Princeton, NJ. Ohm Laboratories produces quality and affordable generic prescription product formulations, as well as OTC medications.

Latest stories

Related stories

Roche Looks to Expand its Drug Production in the US

Roche is planning to expand its drug production in...

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back